This study is exploring a different way to treat children and young adults (ages 1 to 31) with certain solid tumors like rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma, especially if there's a high chance their cancer will return. It uses a treatment called "metronomic therapy," which means giving lower doses of medicines continuously. The study will use a combination of Bevacizumab, Cyclophosphamide, Valproic Acid, and Temsirolimus. The goal is to see if this approach, given after initial treatment when there's minimal disease, can improve how long patients live without their cancer returning. Researchers will also track any side effects. This study aims to enroll 20 participants.

Study design

This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 20 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to five years off therapy to measure how long they live without the cancer returning and to track side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.